X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercepharma.com/pharma/vyvgart-firing-all-cylinders-myasthenia-gravis-argenx-lays-launch-plans-next-potential
https://www.globenewswire.com/news-release/2024/03/27/2852890/0/en/argenx-Advances-Clinical-Development-of-Efgartigimod-in-Primary-Sjogren-s-Disease.html
https://www.globenewswire.com//news-release/2024/01/18/2811228/0/en/argenx-Announces-Approval-of-VYVDURA-efgartigimod-alfa-and-hyaluronidase-qvfc-Injection-for-Subcutaneous-Use-in-Japan-for-Generalized-Myasthenia-Gravis.html
https://www.prnewswire.com/news-releases/halozyme-announces-argenx-received-approval-in-japan-for-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-co-formulated-with-enhanze-for-generalized-myasthenia-gravis-302038081.html
https://www.fiercepharma.com/pharma/argenx-cools-down-its-vyvgart-ambitions-rare-disease-pemphigus-after-trial-flop
https://www.globenewswire.com//news-release/2023/12/20/2799009/0/en/argenx-Reports-Topline-Results-from-ADDRESS-Study-of-Efgartigimod-SC-in-Pemphigus.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761304
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761195
https://www.fiercepharma.com/pharma/argenxs-red-hot-vyvgart-shoots-air-ball-thrombocytopenia-trial
https://endpts.com/injectable-form-of-argenx-drug-vyvgart-fails-phiii-study-in-autoimmune-platelet-disease/
https://www.globenewswire.com//news-release/2023/11/16/2781750/0/en/argenx-Announces-European-Commission-Approval-of-Subcutaneous-VYVGART-efgartigimod-alfa-for-Generalized-Myasthenia-Gravis.html
https://www.fiercepharma.com/pharma/argenxs-vyvgart-continues-its-momentum-strong-uptake-new-subcutaneous-version
https://www.globenewswire.com//news-release/2023/09/15/2743743/0/en/argenx-Announces-Positive-CHMP-Opinion-for-Subcutaneous-Efgartigimod-for-Generalized-Myasthenia-Gravis.html
https://ir.halozyme.com/news/news-details/2023/Positive-Topline-Data-Reported-from-argenxs-ADHERE-Study-of-VYVGART-Hytrulo-with-Halozymes-ENHANZE-Drug-Delivery-Technology-in-Patients-with-Chronic-Inflammatory-Demyelinating-Polyneuropathy/default.aspx
https://www.fiercepharma.com/pharma/vyvgart-shines-cidp-study-teeing-another-potential-nod-argenxs-pipeline-product
https://www.morningstar.com/stocks/argenx-shares-look-undervalued-ahead-key-vyvgart-data-readouts-still-building-moat
https://www.prnewswire.com/news-releases/biocaresd-builds-depth-as-limited-specialty-distributor-by-adding-roctavian-rystiggo-vyvgart-hytrulo-to-portfolio-301873517.html
https://www.biospace.com/article/fda-approves-first-subcutaneous-injectable-for-muscle-weakening-disease-/#:~:text=FDA%20Approves%20First%20Subcutaneous%20Injectable%20for%20Muscle%2DWeakening%20Disease,-Published%3A%20Jun%2021&text=Amsterdam%2Dbased%20argenx%20brings%20another,with%20a%20shot%20at%20home.
https://www.prnewswire.com/news-releases/halozyme-announces-argenx-receives-fda-approval-for-vyvgart-hytrulo-with-enhanze-for-subcutaneous-use-in-generalized-myasthenia-gravis-301855994.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761304
https://ancavasculitisnews.com/news/argenx-proof-of-concept-efgartigimod-trial-aav-expected-2023/
https://www.biospace.com/article/releases/argenx-announces-uk-mhra-approval-of-vyvgart-for-the-treatment-of-generalized-myasthenia-gravis/
https://www.fiercepharma.com/pharma/fda-extends-review-argenxs-subcutaneous-efgartigimod-pushing-decision-date-back-june
https://www.globenewswire.com/news-release/2022/12/10/2571398/0/en/argenx-to-Present-Pivotal-ADVANCE-Trial-Data-During-ASH-Plenary-Session-Highlighting-VYVGART-efgartigimod-alfa-fcab-as-Potential-New-Treatment-Modality-for-Immune-Thrombocytopenia.html
https://www.ema.europa.eu/en/documents/overview/vyvgart-epar-medicine-overview_en.pdf
https://fujifilmdiosynth.com/about-us/press-releases/fujifilm-diosynth-biotechnologies-enters-into-an-agreement-with-argenx-to-manufacture-efgartigimod-a-monoclonal-antibody-mab-for-the-treatment-of-severe-autoimmune-diseases/,
https://www.fiercepharma.com/pharma/seeking-sibling-vyvgart-argenx-files-fda-approval-subcutaneous-efgartigimod
https://www.pharmacompass.com/pdf/news/argenxs-vyvgart-efgartigimod-alfa-receives-approval-in-europe-76666.pdf
https://www.globenewswire.com/news-release/2022/09/21/2519783/0/en/argenx-Submits-Biologics-License-Application-to-U-S-Food-and-Drug-Administration-for-Subcutaneous-Efgartigimod-for-Treatment-of-Generalized-Myasthenia-Gravis.html
https://www.prnewswire.com/news-releases/argenxs-vyvgart-and-alexions-ultomiris-go-toe-to-toe-in-generalized-myasthenia-gravis-according-to-spherix-global-insights-301611961.html
https://www.globenewswire.com/news-release/2022/08/11/2496556/0/en/argenx-Announces-European-Commission-Approval-of-VYVGART-efgartigimod-alfa-fcab-for-the-Treatment-of-Generalized-Myasthenia-Gravis.html
https://www.globenewswire.com/news-release/2022/06/24/2468533/0/en/argenx-Receives-Positive-CHMP-Opinion-for-Efgartigimod-for-the-Treatment-of-Adult-Patients-with-Generalized-Myasthenia-Gravis-in-Europe.html
https://www.prnewswire.com/news-releases/medison-pharma-announces-multi-regional-partnership-agreement-with-argenx-to-commercialize-efgartigimod-across-europe-and-israel-301561651.html
https://www.prnewswire.com/news-releases/positive-topline-results-announced-from-adapt-sc-study-evaluating-subcutaneous-efgartigimod-using-enhanze-drug-delivery-technology-for-generalized-myasthenia-gravis-301507425.html
https://www.contractpharma.com/contents/view_breaking-news/2022-03-01/iqvia-argenx-partner-to-accelerate-clinical-development-of-vyvgart/?widget=listSection
https://www.labiotech.eu/trends-news/argenx-efgartigimod-myasthenia-gravis/
https://www.fiercepharma.com/pharma/argenx-snags-first-fda-approval-efgartigimod-win-generalized-myesthenia-gravis
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761195
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis
https://www.globenewswire.com/news-release/2021/06/16/2248583/0/en/argenx-announces-publication-of-Phase-3-ADAPT-trial-results-of-efgartigimod-for-the-treatment-of-generalized-myasthenia-gravis-in-The-Lancet-Neurology.html
https://www.globenewswire.com/news-release/2021/03/02/2184873/0/en/argenx-Announces-FDA-Acceptance-of-BLA-Filing-for-Efgartigimod-for-the-Treatment-of-Generalized-Myasthenia-Gravis.html#:~:text=Breda%2C%20the%20Netherlands%20%E2%80%93%20March%202,for%20review%20the%20Biologics%20License
Market Place
Share 
